American Association for Cancer Research
Browse

Supplementary Figures 1-10 from Integrin α4β1 Signaling Is Required for Lymphangiogenesis and Tumor Metastasis

Download (1.35 MB)
journal contribution
posted on 2023-03-30, 20:11 authored by Barbara Garmy-Susini, Christie J. Avraamides, Michael C. Schmid, Philippe Foubert, Lesley G. Ellies, Leo Barnes, Chloe Feral, Thalia Papayannopoulou, Andrew Lowy, Sarah L. Blair, David Cheresh, Mark Ginsberg, Judith A. Varner
Supplementary Figures 1-10 from Integrin α4β1 Signaling Is Required for Lymphangiogenesis and Tumor Metastasis

History

ARTICLE ABSTRACT

Recent studies have shown that lymphangiogenesis or the growth of lymphatic vessels at the periphery of tumors promotes tumor metastasis to lymph nodes. We show here that the fibronectin-binding integrin α4β1 and its ligand fibronectin are novel functional markers of proliferative lymphatic endothelium. Tumors and lymphangiogenic growth factors, such as vascular endothelial growth factor-C (VEGF-C) and VEGF-A, induce lymphatic vessel expression of integrin α4β1. Integrin α4β1 then promotes growth factor and tumor-induced lymphangiogenesis, as genetic loss of integrin α4β1 expression in Tie2Cre+ α4loxp/loxp mice or genetic loss of α4 signaling in α4Y991A knock-in mice blocks growth factor and tumor-induced lymphangiogenesis, as well as tumor metastasis to lymph nodes. In addition, antagonists of integrin α4β1 suppress lymphangiogenesis and tumor metastasis. Our studies show that integrin α4β1 and the signals it transduces regulate the adhesion, migration, invasion, and survival of proliferating lymphatic endothelial cells. As suppression of α4β1 expression, signal transduction, or function in tumor lymphatic endothelium not only inhibits tumor lymphangiogenesis but also prevents metastatic disease, these results show that integrin α4β1–mediated tumor lymphangiogenesis promotes metastasis and is a useful target for the suppression of metastatic disease. Cancer Res; 70(8); 3042–51. ©2010 AACR.